American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6371)
  2. Solid Tumor Oncology Division (5512)
  3. Survivorship Research (1988)
  4. Genitourinary Oncology Service (1764)
  5. Surgery (1633)
  6. Epidemiology and Biostatistics (1484)
  7. GSK Faculty (1382)
  8. Population Sciences Research Program (1367)
  9. Gastrointestinal Oncology Service (1351)
  10. Hematologic Malignancies, Division of (1275)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2561)
  3. Editorial (73)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6371)
  2. Solid Tumor Oncology Division (5512)
  3. Survivorship Research (1988)
  4. Genitourinary Oncology Service (1764)
  5. Surgery (1633)
  6. Epidemiology and Biostatistics (1484)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (250)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8678)
  2. JCO Precision Oncology (166)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (4)

More Publications

Results (9142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study
    Meeting Abstract

    Beckermann, K.; Choueiri, T. K.; Motzer, R. J.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P. C.; McKay, R. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study
    Meeting Abstract

    Dizman, N.; Doshi, S. D.; Knezevic, A.; Feinaj, A.; Sayegh, N.; Hobeika, C.; Alaghehbandan, R.; Rives, H.; Zengin, Z. B.; Braun, D. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274
    Meeting Abstract

    Milowsky, M. I.; Galsky, M. D.; Witjes, J. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer
    Meeting Abstract

    McManus, H. D.; Howard, L.; Crowell, K. A.; Hyslop, T.; Autio, K. A.; Rathkopf, D.; Dreicer, R.; Chi, K. N.; Ong, M.; Mateo, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy of (177)Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis
    Meeting Abstract

    Yazdanpanah, O.; Calais, J.; Chi, K. N.; De Bono, J. S.; Deymann, S.; El-Haddad, G.; Herrmann, K.; Fizazi, K.; Gonzalez, D. O.; Kendi, A. T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC)
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D.; Runcie, K.; Zhang, T.; Gotto, G.; Merseburger, A. S.; Dos Santos, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC)
    Meeting Abstract

    Chablani, P. V.; Khaki, A. R.; Tawagi, K.; Grivas, P.; Hoffman-Censits, J.; Galsky, M. D.; Gupta, S.; Koshkin, V. S.; Plimack, E. R.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of (177)Lu-PSMA-617
    Meeting Abstract

    De Bono, J. S.; Morris, M. J.; Sartor, A. O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results
    Meeting Abstract

    Jackson, W. C.; Dess, R. T.; Jia, A. Y.; Nagar, H.; Desai, N. B.; Hannan, R.; Hearn, J. W. D.; Reichert, Z. R.; Marciscano, A. E.; Davis, B.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety
    Meeting Abstract

    Bryce, A. H.; McDermott, R. S.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Bambury, R. M.; Emmenegger, U.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save